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Clinical review
Current concepts in the diagnosis and treatment of
typhoid fever
Zulfiqar A Bhutta
Although advances in public health and hygiene have
led to the virtual disappearance of enteric fever (more
commonly termed typhoid fever) from much of the
developed world, the disease remains endemic in many
developing countries. Typhoid fever is caused by
Salmonella enterica serovar Typhi (S typhi), a Gram
negative bacterium. A similar but often less severe
disease is caused by S paratyphi A and, less commonly,
by S paratyphi B (Schotmulleri) and S paratyphi C (Hir-
schfeldii). The common mode of infection is by inges-
tion of an infecting dose of the organism, usually
through contaminated water or food. Although the
source of infection may vary, person to person
transmission through poor hygiene and sewage
contamination of water supply are the most important.
Have the epidemiology and burden
estimates of typhoid changed?
Few established surveillance systems for typhoid exist
in the developing world, especially in community
settings, so the true burden is difficult to estimate. This
is shown by recent revisions in the global estimates of
the true burden of typhoid. In contrast to previous esti-
mates, which were 60% higher,1 investigators from the
US Centers for Disease Control and Prevention
estimate that there are 21.6 million typhoid cases
annually, with the annual incidence varying from 100
to 1000 cases per 100 000 population.2 The global
mortality estimates from typhoid have also been
revised downwards from 600 000 to 200 000, largely
on the basis of regional extrapolations.2 Recent popu-
lation based studies from South Asia suggest that the
incidence is highest in children aged less than 5 years,
with higher rates of complications and hospitalisation,
and may indicate risk of early exposure to relatively
large infecting doses of the organisms in these
populations.3–5 These findings contrast with previous
studies from Latin Americaw1 and Africa,w2 which
suggested that S typhi infection caused a mild disease in
infancy and childhood.
There may be other factors that affect the changing
epidemiology of typhoid. Although the overall ratio of
disease caused by S typhi to that caused by S paratyphi is
about 10 to 1, the proportion of S paratyphi infections
is increasing in some parts of the world (Dong Mei Tan,
personal communication 2005).6 Also, in contrast to
the Asian situation, the HIV and AIDS epidemic in
Africa has been associated with a concomitant increase
in community acquired bacteraemia due to non-
typhoidal salmonellae such as S typhimurium,7 8 an
illness that may be clinically indistinguishable from
typhoid. The exact reasons for these differences in the
epidemiology and spectrum of salmonella infections
between Asia and Africa remain unclear.
Another worrying development has been the
emergence of drug resistant typhoid. After sporadic
outbreaks of chloramphenicol resistant typhoid
between 1970 and 1985, many strains of S typhi devel-
oped plasmid mediated multidrug resistance to the
three primary antimicrobials used (ampicillin, chlor-
amphenicol, and co-trimoxazole).9 This was countered
by the advent of oral quinolones, but chromosomally
acquired quinolone resistance in S typhi and S
paratyphiw3 has been recently described in various parts
of Asia, possibly related to the widespread and
indiscriminate use of quinolones.10 11
Summary points
Despite advances in technology and public health
strategies, typhoid fever remains a major cause of
morbidity in the developing world
In some areas typhoid fever disproportionately
affects young children and may reflect high rates
of transmission through food and water
Recent emergence of drug resistance—especially
to common, first line antibiotics and
quinolones—has made it very difficult and
expensive for health services to manage the
disease
Rapid and appropriate diagnostics are key to
the management of typhoid in terms of public
health
Although effective vaccines are available, there are
no plans for large scale vaccination programmes
in infants and children
Extra references w1-w19 are on bmj.com
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Can typhoid be diagnosed clinically
where it matters?
Typhoid fever is among the most common febrile
illnesses encountered by practitioners in developing
countries. The advent of antibiotic treatment has led to
a change in the presentation of typhoid, and the classic
mode of presentation with a slow and “stepladder” rise
in fever and toxicity is rarely seen. However, rising anti-
microbial resistance has been associated with increased
severity of illness and related complications.
Many other factors influence the severity and over-
all clinical outcome of the infection. They include the
duration of illness before the start of appropriate treat-
ment, the choice of antimicrobial, the patient’s age and
exposure or vaccination history, the virulence of the
bacterial strain, the quantity of inoculum ingested, and
several host factors affecting immune status. Recent
data from South Asia indicate that the presentation of
typhoid may be more dramatic in children younger
than 5 years, with higher rates of complications and
hospitalisation.3–5 Diarrhoea, toxicity, and complica-
tions such as disseminated intravascular coagulation
are also more common in infancy, with higher mortal-
ity. Table 1 shows some of the common clinical features
and complications of typhoid in children and adults
based on our experience in Karachi of hospitalised
children and those diagnosed and treated in a commu-
nity setting,5 12 indicating the significantly higher
morbidity and complications among children present-
ing to hospital.
The presentation of typhoid fever may be altered
by coexisting morbidities and early administration of
antibiotics. In areas where malaria is endemic and
where schistosomiasis is common the presentation of
typhoid may be atypical.13 14 Multidrug resistant
typhoid and paratyphoid infections are more severe
with higher rates of toxicity, complications, and
mortality than infections with sensitive strains.12 This
may be related to the increased virulence of multidrug
resistant S typhi as well as a higher number of circulat-
ing bacteria.15 Although clinical diagnosis of typhoid
may be difficult, there are indications that simple algo-
rithms can be developed for diagnosis and patient
triage in endemic areas.16 Such algorithms would have
implications for diagnostic and treatment protocols in
endemic areas: in particular, diagnosis and triage of
typhoid among febrile children must be included
among the protocols for integrated management of
childhood illnesses in South Asia, which currently
largely focus on malaria as a cause of fever without
localising signs.
The challenge of appropriate diagnostics
in typhoid
Although the mainstay of diagnosing typhoid fever is a
positive blood culture, the test is positive in only
40-60% of cases,17 usually early in the course of the dis-
ease. Stool and urine cultures become positive after the
first week of infection, but their sensitivity is much
lower. In much of the developing world, widespread
antibiotic availability and prescribing is another reason
for the low sensitivity of blood cultures. Although bone
marrow cultures are more sensitive, they are difficult to
obtain, relatively invasive, and of little use in public
health settings.
Other haematological investigations are non-
specific. Blood leucocyte counts are often low in
relation to the fever and toxicity, but the range is wide;
in younger children leucocytosis is a common associa-
tion andmay reach 20 000-25 000/mm3.12 w4 Thrombo-
cytopenia may be a marker of severe illness and
accompany disseminated intravascular coagulation.
Liver function test results may be deranged, but signifi-
cant hepatic dysfunction is rare.
The classic Widal test measures antibodies against
O and H antigens of S typhi and is more than 100
years old.w5 Although robust and simple to perform,
Sources and selection criteria
We evaluated all recent clinical reviews of typhoid
fever in the electronic data bases (Medline, PubMed,
Embase, and the Cochrane Library) for the past 10
years (1996-2006) in all languages to identify critical
reviews and systematic reviews on the risk factors,
diagnosis, treatment, and prevention of typhoid and
paratyphoid fever. The focus was on clinical
publications on epidemiology, diagnosis, and
treatment, but we also studied other related reviews
and publications.
Although several reviews of typhoid fever and
treatment are available, there have been few systematic
reviews and meta-analyses of treatment strategies, with
only one Cochrane review of treatment options and
none on appropriate diagnostics for typhoid.
The main search terms used were “typhoid fever,”
“paratyphoid fever,” “enteric fever,” “typhoidal
salmonellosis,” and “Salmonella” in combination with
“Typhi” or “Paratyphi.” We also perused relevant
reports from the World Health Organization and
Centers for Disease Control and Prevention and the
abstracts from five international symposiums on
typhoid fever and other salmonelloses (Bangkok 1994,
Bali 1997, Taipei 1999, Karachi 2002, and Guilin
2005).
We carried out a manual search of the
bibliographies of key articles and reviews. In all, we
studied 156 recent articles in depth, of which 44 are
cited in this review.
Table 1 Common clinical features of typhoid fever in childhood
in hospital and community settings in Karachi, Pakistan. Values
are numbers (percentages)
Hospital based patients
(n=1158)*
Community based cohort
(n=340)†
High grade fever 1044 (95) 338 (99)
Anorexia 811 (70) 11 (3)
Vomiting 451 (39) 43 (13)
Hepatomegaly 471 (41) 68 (20)
Diarrhoea 406 (35) 26 (8)
Toxicity 377 (33) 1 (0.3)
Abdominal pain 320 (28) 65 (19)
Splenomegaly 226 (20) 17 (5)
Constipation 127 (11) 1 (0.3)
Headache 138 (12) 26 (8)
Jaundice 23 (2) 0
Obtundation 23 (2) 1 (0.3)
Ileus 12 (1) 1 (0.3)
Intestinal perforation 58 (0.5) 1 (0.3)
Myalgia 174 (15) 15 (4.4)
*Data from Bhutta 1996.12
†Data from Siddiqui et al 2006.5
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this test lacks sensitivity and specificity, and reliance on
it alone in areas where typhoid is endemic may lead to
overdiagnosis.w6 Newer diagnostic tests have been
developed—such as the Typhidotw7 w8 or Tubex,w9 w10
which directly detect IgM antibodies against a host of
specific S typhi antigens—but these have not proved to
be sufficiently robust in large scale evaluations in com-
munity settings. A nested polymerase chain reaction
using H1-d primers has been used to amplify specific
genes of S typhi in the blood of patients and is a prom-
ising means of making a rapid diagnosis.w11 Table 2
compares the performance of the various tests for
typhoid.w12-w14
Despite these new developments, the diagnosis of
typhoid in much of the developing world is made on
clinical criteria. This poses problems, since typhoid
fever may mimic many common febrile illnesses with-
out localising signs. In children with multisystem
features, the early stages of enteric fever may be
confused with conditions such as acute gastroenteritis,
bronchitis, and bronchopneumonia. Subsequently, the
differential diagnosis includes malaria; sepsis with
other bacterial pathogens; infections caused by intra-
cellular organisms such as tuberculosis, brucellosis,
tularaemia, leptospirosis, and rickettsial diseases; and
viral infections such as dengue fever, acute hepatitis,
and infectious mononucleosis. There is thus an urgent
need to develop a multipurpose “fever stick” that may
allow the rapid and specific diagnosis of common
febrile illnesses, especially malaria, dengue fever, and
typhoid.w15
How has drug resistance affected
treatment?
Early diagnosis of typhoid fever and prompt institution
of appropriate antibiotic treatment are essential for
optimal management, especially in children. Although
most cases can be managed at home with oral anti-
biotics and regular follow-up, patients with severe
illness, persistent vomiting, severe diarrhoea, and
abdominal distension require hospitalisation and
parenteral antibiotic treatment. In addition to anti-
biotics, supportive treatment and maintenance of
appropriate nutrition and hydration are crucial
(box 1).
Appropriate antibiotic treatment (the right drug,
dose, and duration) is critical to curing typhoid with
minimal complications.18 Standard treatment with
chloramphenicol or amoxicillin is associated with a
relapse rate of 5-15% or 4-8% respectively, whereas the
newer quinolones and third generation cephalo-
sporins are associated with higher cure rates.17 The
emergence of multidrug resistant typhoid in the 1990s
led to widespread use of fluoroquinolones as the treat-
ment of choice for suspected typhoid, especially in
South Asia and South East Asia where the disease was
Table 2 Laboratory diagnosis of typhoid
Diagnostic test Sensitivity range (%) Specificity range (%) Comments
Microbiological tests
Blood culture 40-80 NA Widely regarded as the gold standard, but sensitivity may be low
in endemic areas with high rates of antibiotic use—hence true
specificity is difficult to estimate
Bone marrow cultures 55-67 30 Greater sensitivity but invasive and thus of limited clinical value,
especially in ambulatory management
Urine culture 0-58 NA Variable sensitivity
Stool culture 30 NA Sensitivity lower in developing countries and not used routinely
for follow-up
Molecular diagnostics
Polymerase chain reaction 100 100 Promising, but initial reports indicated similar sensitivity to blood
cultures and lower specificity
Nested polymerase chain reaction 100 100 Promising and may replace blood culture as the new “gold
standard”
Serological diagnosis
Widal test (tube dilution and slide
agglutination)
47-77 50-92 Classic and inexpensive. Despite mixed results in endemic areas,
still performs well for screening large volumes. May need
standardisation and quality assurance of reagents
Typhidot 66-88 75-91 Lower sensitivity than Typhidot-M
Typhidot-M 73-95 68-95 Higher sensitivity and specificity than classic Typhidot in some
series, but other evaluations suggest that the performance may
not be as robust in community settings as in hospital
Tubex 65-88 63-89 Promising initial results but has yet to be evaluated in larger trials
in community settings
Others
Urine antigen detection 65-95 NA Preliminary data only
NA=Not available.
Box 1: General principles for the management
of typhoid
• Rapid diagnosis and institution of appropriate
antibiotic treatment
• Adequate rest, hydration, and correction of
fluid-electrolyte imbalance
• Antipyretic therapy as required (such as
paracetamol 120-750 mg taken orally every 4-6 hours)
• Adequate nutrition: a soft, easily digestible diet
should be continued unless the patient has abdominal
distension or ileus
• Close attention to hand washing and limitation of
close contact with susceptible individuals during acute
phase of infection
• Regular follow-up and monitoring for complications
and clinical relapse (this may include confirmation of
stool clearance in non-endemic areas or in high risk
groups such as food handlers)
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endemic.19 In recent years, however, the emergence of
resistance to quinolones has placed tremendous
pressure on public health systems in developing coun-
tries as treatment options are limited.20 21
Table 3 shows the World Health Organization’s
recommendations for treating uncomplicated and
severe cases of typhoid fever.17 Studies of short course
antibiotic treatment for multidrug resistant typhoid
have shown that fluoroquinolones can achieve satisfac-
tory cure rates,w16 w17 but parenteral ceftriaxone was
associated with higher rates of relapse.w18 A recent
Cochrane review of antimicrobial treatment of typhoid
fever concludes that there is little evidence to support
administration of fluoroquinolones to all cases of
typhoid and that satisfactory cure rates can be achieved
in drug sensitive cases with first line agents such as
chloramphenicol.22 Although some open studies have
suggested that cure rates may be better with oral
fluoroquinolones compared with chloramphenicol,23
these case series also include multidrug resistant cases.
Given the signs of rapidly increasing resistance of S
typhi to fluoroquinolones, it is imperative that the wide-
spread use of these antibiotics for fever and their avail-
ability over the counter are restricted, although it may
already be too late.24 However, treatment regimens
must restrict as much as possible the use of further sec-
ond and third line antibiotics for treating typhoid in
primary care settings.25
The prognosis for a patient with enteric fever
depends on the rapidity of diagnosis and treatment
with an appropriate antibiotic. Other factors include
the patient’s age, general state of health, and nutrition;
the causative Salmonella serotype; and the appearance
of complications. Infants and children with underlying
malnutrition and those infected with multidrug
resistant isolates are at higher risk of adverse
outcomes. Although additional treatment with dexa-
methasone (3 mg/kg for the initial dose, followed
by 1 mg/kg every 6 hours for 48 hours) has been
recommended among severely ill patients with shock,
obtundation, stupor, or coma,w19 this must be done
only under strictly controlled conditions and super-
vision, and signs of abdominal complications may be
masked.
Despite appropriate treatment, some 2-4% of
infected children relapse after initial clinical response
to treatment.17 Individuals who excrete S typhi for more
than three months after infection are regarded as
chronic carriers. However, the risk of becoming a
carrier is low in children and increases with age, but in
general it occurs in less than 2% of all infected
children.17
In summary, many challenges remain for the effec-
tive control and management of typhoid in endemic
countries. Although these include establishing rapid
clinical diagnosis and confirmation, the fact that both S
typhi and S paratyphi are rapidly becoming resistant
Table 3 Recommended antibiotic treatment for typhoid fever (adapted from WHO17 and Bhutta20)
Susceptibility
Optimal treatment Alternative effective treatment
Drug
Daily dose
(mg/kg)
Course
(days) Drug Daily dose (mg/kg) Course (days)
Uncomplicated typhoid fever
Fully sensitive Fluoroquinolone (such as
ofloxacin or ciprofloxacin)
15 5-7* Chloramphenicol 50-75 14-21
Amoxicillin 75-100 14
TMP-SMX 8-40 14
Multidrug
resistance
Fluoroquinolone or 15 5-7 Azithromycin 8-10 7
Cefixime 15-20 7-14 Cefixime 15-20 7-14
Quinolone
resistance†
Azithromycin or 8-10 7 Cefixime
20 7-14
Ceftriaxone 75 10-14
Severe typhoid fever requiring parenteral treatment
Fully sensitive Fluoroquinolone (such as
ofloxacin)
15 10-14 Chloramphenicol 100 14-21
Ampicillin 100 14
TMP-SMX 8/40 14
Multidrug
resistant
Fluoroquinolone 15 10-14 Ceftriaxone or 60
10-14
Cefotaxime 80
Quinolone
resistant
Ceftriaxone or 60
10-14
Fluoroquinolone
20 14
Cefotaxime 80
*Three day courses also effective, particularly so in epidemic containment.
†Optimum treatment for quinolone resistant typhoid fever has not been determined. Azithromycin, third generation cephalosporins, or a 10-14 day course of high
dose fluoroquinolone is effective. Combinations of these are now being evaluated.
Box 2: Advice for travellers to areas where
typhoid is endemic
• Avoid undue exposure to possible infection through
food and water (contaminated water, salads, street
foods). Use bottled water whenever possible, otherwise
use only boiled water
• Two typhoid vaccines are available, both with proved
efficacy of 60-80%, and should be taken at least two
weeks before travel
Oral Ty21a vaccine—Enteric coated capsules taken on
alternate days for four doses. The vaccine is
contraindicated in pregnant women, children under
the age of 6 years, and immunocompromised
patients. A booster may be required every five years
Vi polysaccharide vaccine—0.5 ml as a single
intramuscular dose for travellers older than 2 years.
A booster may be required every two years
• Further advice on typhoid prevention and
vaccination can be obtained from
Centers for Disease Control and Prevention
(www.cdc.gov/travel)
World Health Organization (www.who.int/ith)
International Society of Travel Medicine
(www.istm.org)
Travel Doctor (www.traveldoctor.co.uk/diseases.htm)
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to commonly used antibiotics is of great concern.
Addressing this issue would require a host of measures,
including adequate investments in safe water and sani-
tation services, community education, control over
antimicrobial prescribing and over the counter sales,
and large scale vaccination strategies. Box 2 details
some of the preventive strategies and advice for travel-
lers to areas where typhoid is endemic.
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Separating a septum sandwich
A 7 year old boy had inquisitively removed two small
circular magnets attached to the bottom of his toy car.
He then inserted one up each nostril. The magnets
were immediately drawn to each other, clamping
firmly on to either side of his nasal septum.
On his arrival in the accident and emergency
department, various manual manoeuvres with metal
instruments were attempted, but these were attracted
to each magnet with a resounding “clunk,” provoking
squeals of pain from the child as doctors grappled to
remove the adherent instruments. Plastic instruments
failed to provide sufficient grip on the slippery edges
of the magnets. Doctors and patient were becoming
more frustrated, with the latter increasingly reluctant to
let anyone near his nose. A powerful pacemaker
resetting magnet was brought down from the coronary
care unit, but this attracted both small magnets, pulling
the septum forward. Vaseline was applied to both sides
of his septum in the hope of slipping the magnets off,
but it only made a sticky situation even stickier.
Three hours after the provoking event, I was called
to see the patient. The likelihood of septal necrosis
with perforation and infection was increasing each
minute, just as the child’s faith in the medical
profession was diminishing. Understandably, he was
anxious to prevent any further attempts to remove the
magnets and cupped both hands protectively over his
nose, turning away to sob despairingly into his
mother’s bosom.
After much coaxing, I had to promise the boy that
my attempt would be successful. I then obtained a pair
of Blakesley forceps, usually used to perform
functional endoscopic sinus surgery, from theatre. A
nurse grasped his head firmly, his distraught mother
held his left hand, and the senior house officer held his
right. He shut his eyes and braced himself at the sight
of the approaching forceps. With a deep breath from
the patient and myself, a quick lateral tug dislodged the
magnet from the septum, such that it stuck to the
Blakesley forceps. The remaining magnet was easily
retrieved as it had fallen off the septum.
Separating the septum sandwich had taken a long
time, not to perform the actual procedure itself but to
comfort and gently persuade the boy into allowing me
one final attempt. Crucially, the promise I made him
meant that there was no room for error. Children, even
more so than adults, take promises very seriously, and
broken promises are difficult to understand and
accept. Fortunately, I managed to keep my word and
was rewarded with the beaming smile of a relieved
child.
A C Leong ENT specialist registrar,Medway Maritime
Hospital, Gillingham,Kent
(Annabelle.Leong@btinternet.com)
We welcome articles up to 600 words on topics such as
A memorable patient, A paper that changed my practice,My
most unfortunate mistake,or any other piece conveying
instruction, pathos, or humour. Please submit the
article on http://submit.bmj.com Permission is needed
from the patient or a relative if an identifiable patient is
referred to. We also welcome contributions for
“Endpieces,” consisting of quotations of up to 80 words
(but most are considerably shorter) from any source,
ancient or modern, which have appealed to the reader.
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